Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.47 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 5/20 | 0.44 |
| ▸ | NPY1R | P25929 | 4/20 | 0.44 |
| ▸ | GLP1R | P43220 | 4/20 | 0.44 |
| ▸ | NPY2R | P49146 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.43 |
| ▸ | CALCR | P30988 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221849 | 0.87 | C5AR1 (0.56) | C5AR1GLP1RCALCRCRHR1CRHR2 | |
| SCHEMBL18888624 | 0.86 | C5AR1 (0.60) | C5AR1NPY4RNPY1RGLP1RNPY2R | |
| SCHEMBL23895415 | 0.85 | C5AR1 (0.47) | C5AR1GLP1R | |
| SCHEMBL23895409 | 0.83 | C5AR1 (0.45) | C5AR1VIPR1GLP1RCALCR | |
| SCHEMBL18888623 | 0.82 | C5AR1 (0.58) | C5AR1NPY4RNPY1RGLP1RNPY2R | |
| SCHEMBL23895425 | 0.82 | C5AR1 (0.45) | C5AR1NPY4RNPY1RGLP1RNPY2R | |
| SCHEMBL23895427 | 0.82 | C5AR1 (0.45) | C5AR1NPY4RNPY1RGLP1RNPY2R | |
| SCHEMBL29710470 | 0.82 | C5AR1 (0.50) | C5AR1NPY4RNPY1RGLP1RNPY2R | |
| SCHEMBL30512623 | 0.82 | PTH1R (0.50) | C5AR1PTH1RVIPR1CALCRKEAP1 | |
| SCHEMBL19221754 | 0.81 | C5AR1 (0.56) | C5AR1NPY4RNPY1RGLP1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308211-A1 | METHOD OF TREATING VIRAL INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308211-A1 | METHOD OF TREATING VIRAL INFECTIONS | IRF3, IRF2BP2, STAT4 | C5AR1 1292/4885PTH1R 4804/4885VIPR1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.